Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Trey Thoelcke | Jan 22, 2014 at 7:30 AM EST

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Teva Pharmaceutical resume a deal-making strategy that made it one of the most acquisitive drug companies of the past decade.…

Jon C. Ogg | Jan 16, 2014 at 8:15 AM EST

Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential

The analysts at Piper Jaffray have returned from meeting with some of the top biotechs the cover, and they have…

Trey Thoelcke | Jan 16, 2014 at 7:05 AM EST

Strong Growth Lifts UnitedHealth Earnings

Before markets opened Thursday morning, UnitedHealth Group reported fourth-quarter and full-year 2013 results that topped consensus estimates on the top…

Jon C. Ogg | Jan 15, 2014 at 11:35 AM EST

Can Chelsea Live Up to Its Potential This Time?

Chelsea Therapeutics International is on the leader board for percentage gains on Thursday, with a rise of 111% or so.…

Jon C. Ogg | Jan 14, 2014 at 8:15 AM EST

UBS Has Nine Biotech Buyout and Merger Candidates

The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility…

Jon C. Ogg | Jan 13, 2014 at 12:10 PM EST

Higher 2017 Celgene Guidance Keeps Confusion in Near-Term

Celgene has issued its preliminary numbers ahead of its presentations at the 32nd Annual J.P. Morgan Healthcare Conference. There is…

Jon C. Ogg | Jan 10, 2014 at 2:36 PM EST

Volatility and Options in MannKind Shaking Speculators Out

ThinkstockMannKind Corp. (NASDAQ: MNKD) is a stock that has been on a wild ride for many years. The company’s inhalable…

Jon C. Ogg | Jan 10, 2014 at 9:05 AM EST

Scorching Hot Biotech Tape: Small-Cap and Mid-Cap Stocks on Fire

Piper Jaffray analyst have a list of top biotech stock picks that could bring big gains for investors. The look…

Trey Thoelcke | Jan 9, 2014 at 8:45 AM EST

Merrill Lynch Top Medical Technology Stocks to Buy for 2014

At this time last year, the sentiment on Wall Street for the medtech sector was very poor. The bearish sentiment…

Jon C. Ogg | Jan 8, 2014 at 9:05 AM EST

The Bullish and Bearish Case for UnitedHealth in 2014

UnitedHealth Group is still relatively new as a member of the Dow Jones Industrial Average. Its stock gained a whopping…

Jon C. Ogg | Jan 8, 2014 at 8:10 AM EST

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going…

Jon C. Ogg | Jan 7, 2014 at 8:51 AM EST

The Bullish and Bearish Case for Pfizer and Merck in 2014

With a new year comes new expectations. 24/7 Wall St. has generated a bullish and bearish scenario for 2014 in…

Jon C. Ogg | Jan 7, 2014 at 8:25 AM EST

Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More

The team at Oppenheimer has a list of biotech stocks to buy that feature catalysts that could be game changers.…

Jon C. Ogg | Jan 3, 2014 at 8:30 AM EST

Biotech Stocks Under $10 With Huge Upside Potential for 2014

24/7 Wall St. ran a screen of the Wall Street firms we cover looking for biotech stocks trading under $10…

Trey Thoelcke | Dec 19, 2013 at 8:30 AM EST

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.

1 … 295 296 297 298 299 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential

Strong Growth Lifts UnitedHealth Earnings

Can Chelsea Live Up to Its Potential This Time?

UBS Has Nine Biotech Buyout and Merger Candidates

Higher 2017 Celgene Guidance Keeps Confusion in Near-Term

Volatility and Options in MannKind Shaking Speculators Out

Scorching Hot Biotech Tape: Small-Cap and Mid-Cap Stocks on Fire

Merrill Lynch Top Medical Technology Stocks to Buy for 2014

The Bullish and Bearish Case for UnitedHealth in 2014

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

The Bullish and Bearish Case for Pfizer and Merck in 2014

Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More

Biotech Stocks Under $10 With Huge Upside Potential for 2014

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

ISPY’s 0.56% Fee Hides a $38,000 Decade-Long Performance Gap Against SPY

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

Health and Healthcare Articles

All Health and Healthcare Articles

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential

Strong Growth Lifts UnitedHealth Earnings

Can Chelsea Live Up to Its Potential This Time?

UBS Has Nine Biotech Buyout and Merger Candidates

Higher 2017 Celgene Guidance Keeps Confusion in Near-Term

Volatility and Options in MannKind Shaking Speculators Out

Scorching Hot Biotech Tape: Small-Cap and Mid-Cap Stocks on Fire

Merrill Lynch Top Medical Technology Stocks to Buy for 2014

The Bullish and Bearish Case for UnitedHealth in 2014

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

The Bullish and Bearish Case for Pfizer and Merck in 2014

Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More

Biotech Stocks Under $10 With Huge Upside Potential for 2014

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

ISPY’s 0.56% Fee Hides a $38,000 Decade-Long Performance Gap Against SPY

Featured Reads

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income